Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Dec 9, 2010


Arrowhead Research, the parent firm of Calando Pharmaceuticals, said that Douglass Given has joined its board of directors.

Given is currently chairman and CEO of Vivaldi Biosciences, chairman of Via Pharmaceuticals, and an investment partner at Bay City Capital.

Alnylam Pharmaceuticals has appointed Marsha Fanucci to its board of directors.

Fanucci is the former CFO of Millennium Pharmaceuticals, and currently sits on the board of Ironwood Pharmaceuticals and Momenta Pharmaceuticals.

She previously served as vice president of corporate development and strategy at Genzyme.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.